高橋　孝雄 （タカハシ　タカオ）

Takahashi, Takao

写真a

所属（所属キャンパス）

医学部 （三田）

職名

名誉教授

外部リンク
このページの先頭へ▲

プロフィール 【 表示 ／ 非表示 】

  • 1982年3月　慶應義塾大学医学部卒業 1982年5月　慶應義塾大学医学部研修医(小児科) 1988年9月　米国ハーバード大学、マサチューセッツ総合病院小児神経科 1992年6月　ハーバード大学医学部、Instructor in Neurology 1994年6月　マサチューセッツ総合病院神経科、Assistant in Neurology 1994年8月　慶應義塾大学助手(医学部小児科学) 1996年10月 慶應義塾大学専任講師(医学部小児科学) 1999年4月　慶應義塾大学助教授(医学部小児科学) 2002年4月　慶應義塾大学教授(医学部小児科学) 2007年10月 慶應義塾大学病院　副病院長 2015年10月 慶應義塾大学医学部　医学部長補佐

このページの先頭へ▲

学歴 【 表示 ／ 非表示 】

  • 1976年04月
    -
    1982年03月

    慶應義塾大学医学部

    大学, 卒業

このページの先頭へ▲

学位 【 表示 ／ 非表示 】

  • 医学博士, 慶應義塾大学, 1991年06月

このページの先頭へ▲
 

研究キーワード 【 表示 ／ 非表示 】

  • 大脳皮質発生、神経前駆細胞、高次能機能発達、環境因子、エピジェネティクス

このページの先頭へ▲

研究テーマ 【 表示 ／ 非表示 】

  • 大脳皮質発生、神経前駆細胞、高次能機能発達、環境因子、エピジェネティクス, 

    1982年
    -
    継続中

このページの先頭へ▲
 

著書 【 表示 ／ 非表示 】

  • ガイドラインと最新文献で学ぶ小児科学レビュー２０１６－１７

    高橋孝雄，藤村公乃，三橋隆行., 総合医学社, 2016年05月

    担当範囲: 脳形成異常

  • 続・イメージからせまる小児神経疾患50 ―症例から学ぶ 診断・治療プロセス―

    三橋隆行，高橋孝雄．, 診断と治療社, 2015年11月

    担当範囲: 脳回形成メカニズムと大脳皮質内神経細胞数の変動について

  • 発達科学入門2 胎児期～児童期

    三橋 隆行,吉井 聡, 高橋 孝雄, 東京大学出版会、東京, 2012年02月

    担当範囲: 3-19

  • Encyclopedia of Neuroscience

    Mitsuhashi T, Takahashi T., Springer-Verlag, Berlin, 2009年

    担当範囲: 588-591

  • 新体系看護学２９　小児看護学②

    高橋 孝雄高橋孝雄, 2003年

    担当範囲: 281-291

全件表示 >>

このページの先頭へ▲

論文 【 表示 ／ 非表示 】

  • Pediatric acquired demyelinating syndrome (ADS) in inpatient hospital settings: The hospitalization rate, costs, and outcomes in the US

    Minegishi M., Takahashi T., Testa M.

    Multiple Sclerosis and Related Disorders （Multiple Sclerosis and Related Disorders）  34   150 - 157 2019年09月

    ISSN  22110348

    　概要を見る

    © 2019 Elsevier B.V. Background: Although relatively rare among pediatric patients, acquired demyelinating syndromes of the central nervous system (ADS) is a potentially disabling condition that warrants hospitalization and long-term follow-up. As such, a better understanding of the epidemiology and hospital utilization for this condition could provide critical information for health care planning and resource allocation. Objective: To evaluate the trends of hospital utilization and resource use associated with pediatric ADS in the US. Method: We conducted a serial cross-sectional trend analysis with complex sampling and weighting using nationally representative hospital discharge records, from the Kids´ Inpatient Database (KID), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality coded with International Classification of Diseases (Healthcare Cost and Utilization Project (HCUP) 2018), Ninth Revision (ICD-9-CM) for the years 2003, 2006, 2009, and 2012. We also conducted a cross-sectional study for the KID2016 dataset coded with ICD10-CM to estimate the pediatric ADS-related hospital utilization for the year. Excluding transferring discharges: we evaluated the discharge records for those aged 0 to 19 years diagnosed with any of ADS of central nervous systems including multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), acute disseminated encephalomyelitis (ADEM), optic neuritis (ON), transverse myelitis (TM) and demyelinating disease not specified (DDNS). For the trend analysis, we used variance-weighted regression and Poisson regression for the annual hospitalization rate, total hospital charges and hospital days associated with the ADS hospitalizations for the year 2003 to 2012. Results: We estimated a total of 1,292 ADS-related hospitalizations (95%CI: 1127–1,458) in 2003, 2104 hospitalizations (95%CI: 1823–2385) in 2006, 2851 hospitalizations (95%CI: 2499–3203) in 2009, and 3501 hospitalizations (95%CI: 3058–3945) in 2012 among those aged 19 years or younger with diagnoses of ADS. There was an increase in the proportion of the inpatient hospital cost attributed to ADS from 0.06% in 2003 to 0.20% in 2012. The annual hospitalization rates relative to pediatric ADS were 1.59/100,000 (95%CI: 1.51–1.68) in 2003 and 4.21/100,000 (95%CI: 4.07–4.35) in 2012. In the cross-sectional analysis for the year 2016 coded by ICD10-CM, the number of pediatric ADS related hospitalizations were 4,568, constituting 0.30% of the total pediatric hospitalization cost. The annual hospitalization rate for the year 2016 was estimated to be 5.51/100,000. Conclusion: Hospital utilization by pediatric patients with ADS increased during the period 2003 through 2012. The cross-sectional analysis for the year 2016 indicated that the trend could be ongoing, although the direct comparison was not feasible due to the changes in the coding system of the dataset from ICD9-CM to ICD10-CM. Although relatively rare, pediatric ADS warrant long-term follow-ups and hospitalizations, impacting the developmental trajectory of the affected children and the lives of their family members. Th potentially increasing trend of pediatric ADS hospital utilization should be acknowledged when allocating and planning future resources and supporting programs.

  • Noninvasive diagnosis of TRIT1-related mitochondrial disorder by measuring i<sup>6</sup>A37 and ms<sup>2</sup>i<sup>6</sup>A37 modifications in tRNAs from blood and urine samples

    Takenouchi T., Wei F., Suzuki H., Uehara T., Takahashi T., Okazaki Y., Kosaki K., Tomizawa K.

    American Journal of Medical Genetics, Part A （American Journal of Medical Genetics, Part A）  179 （ 8 ） 1609 - 1614 2019年08月

    ISSN  15524825

    　概要を見る

    © 2019 Wiley Periodicals, Inc. Subsets of mitochondrial transfer RNA (tRNA) contain the N6-isopentenyladenosine (i6A) or 2-methylthio-N6-isopentenyladenosine (ms2i6A) modification at position A37, which is adjacent to an anticodon. These modifications are essential for efficient protein translation in mitochondria and contribute to energy metabolism. The first step in i6A and ms2i6A modifications is catalyzed by tRNA isopentenyltransferase, which is encoded by the TRIT1 gene. Herein, we report a girl with a developmental delay, frequent episodes of seizures induced by febrile illness, and myoclonic epilepsy who had compound heterozygous missense mutations in TRIT1. A mass spectrometry analysis of RNA nucleoside obtained from the subject's peripheral blood and urine showed a marked decrease in both i6A and ms2i6A modifications. These results suggest that the mitochondrial disorder was caused by defective tRNA isopentenylation arising from a loss-of-function mutation in TRIT1. Furthermore, the present observations suggest that noninvasive biochemical analysis using peripheral blood and urine samples are sufficient for the diagnosis of TRIT1-related disorders, making muscle biopsy for the direct measurement of oxidative phosphorylation unnecessary. Such biochemical analyses before the start of antiepileptic medications would be beneficial to avoid hepatotoxicity in patients with possible mitochondrial disorders.

  • Effectiveness of inactivated influenza vaccine in children by vaccine dose, 2013–18

    Shinjoh M., Sugaya N., Furuichi M., Araki E., Maeda N., Isshiki K., Ohnishi T., Nakamura S., Yamada G., Narabayashi A., Nishida M., Taguchi N., Nakata Y., Yoshida M., Tsunematsu K., Shibata M., Munenaga T., Hirano Y., Ookawara I., Sekiguchi S., Kobayashi Y., Yamaguchi Y., Yoshida N., Mitamura K., Takahashi T.

    Vaccine （Vaccine）  37 （ 30 ） 4047 - 4054 2019年07月

    ISSN  0264410X

    　概要を見る

    © 2019 Elsevier Ltd Objectives: We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) by vaccine dose in children aged 6 months to 12 years for whom two doses are recommended in Japan to ascertain the appropriate vaccine doses. Methods: VE was assessed according to a test-negative case-control design based on rapid influenza diagnostic test (RIDT) results. Children aged 6 months to 12 years with a fever ≥38 °C who had received an RIDT in outpatient clinics of 24 hospitals were enrolled for all five seasons since 2013/14. VE by vaccine dose (none vs. once or twice, and once vs. twice) was analyzed. Results: In the dose analysis, 20,033 children were enrolled. Both one- and two-dose regimens significantly reduced cases in preventing any influenza, influenza A, and influenza B, but there was no significant difference in adjusted VE between one- and two-dose regimens overall (adjusted OR, 0.560 [95% CI, 0.505–0.621], 0.550 [95% CI, 0.516–0.586]), 0.549 [95% CI, 0.517–0.583], and 1.014 [95% CI, 0.907–1.135], for none vs. once, none vs. twice, none vs. once or twice, and once vs. twice for any influenza, respectively). Both one- and two-dose regimens significantly reduced cases with any influenza and influenza A every season. Also, both regimens significantly reduced cases of any influenza, influenza A, and influenza B among children aged 1–12 years, especially among those aged 1–5 years. In the 2013/14, 2015/16, and 2016/17 seasons, however, only the two-dose regimen was significantly effective in preventing influenza B. Both one- and two-dose regimens significantly reduced cases involving hospitalization due to any influenza and influenza A. Conclusions: Both one- and two-doses regimens of IIV were effective in preventing influenza for children aged 6 months to 12 years. The two-dose regimen was more effective against influenza B in some seasons.

  • Further evidence of a causal association between AGO1, a critical regulator of microRNA formation, and intellectual disability/autism spectrum disorder

    Sakaguchi A., Yamashita Y., Ishii T., Uehara T., Kosaki K., Takahashi T., Takenouchi T.

    European Journal of Medical Genetics （European Journal of Medical Genetics）  62 （ 6 ）  2019年06月

    ISSN  17697212

    　概要を見る

    © 2018 Elsevier Masson SAS Among the many regulators of microRNA formation, Argonaute 1 (AGO1) plays critical roles in RNA interference, which controls a wide range of biological activities. Recent large-scale genomic studies have identified at least five patients with intellectual disability/autism spectrum disorder who had de novo mutations in AGO1, but detailed clinical information was not available. The recognizable clinical features that are associated with AGO1 mutations remain to be determined. The proposita was a 15-year-old girl with diffuse hypotonia, infrequent seizures, and intellectual disability with an intelligence quotient of 41. She had characteristic facial features consisting of telecanthus, wide nasal bridge with bulbous nasal tip, and a round face with downslanted palpebral fissures. Serial computed tomography scans showed progressive calcification in the globus pallidus that became evident during childhood. A whole exome analysis in trio revealed a de novo heterozygous mutation in AGO1, i.e., c.595G > A p.(Gly199Ser). The distinctive facial features, i.e., telecanthus, wide nasal bridge with bulbous nasal tip, and a round face with downslanted palpebral fissures, closely resembled previously reported patients who had a chromosomal microdeletion encompassing AGO1 locus. The combinatory phenotype of such characteristic facial features and radiographic features, i.e. progressive calcification in the globus pallidus, in the presently reported patient suggest that AGO1 mutations lead to a syndromic form of intellectual disability/autism spectrum disorder. Distinctive facial features with early and progressive calcification in the globus pallidus may be suggestive of the presence of AGO1 mutations.

  • Large-area fluorescence and electron microscopic correlative imaging with multibeam scanning electron microscopy

    Shibata S., Iseda T., Mitsuhashi T., Oka A., Shindo T., Moritoki N., Nagai T., Otsubo S., Inoue T., Sasaki E., Akazawa C., Takahashi T., Schalek R., Lichtman J., Okano H.

    Frontiers in Neural Circuits （Frontiers in Neural Circuits）  13 2019年04月

    ISSN  16625110

    　概要を見る

    © 2019 Shibata, Iseda, Mitsuhashi, Oka, Shindo, Moritoki, Nagai, Otsubo, Inoue, Sasaki, Akazawa, Takahashi, Schalek, Lichtman and Okano. Recent improvements in correlative light and electron microscopy (CLEM) technology have led to dramatic improvements in the ability to observe tissues and cells. Fluorescence labeling has been used to visualize the localization of molecules of interest through immunostaining or genetic modification strategies for the identification of the molecular signatures of biological specimens. Newer technologies such as tissue clearing have expanded the field of observation available for fluorescence labeling; however, the area of correlative observation available for electron microscopy (EM) remains restricted. In this study, we developed a large-area CLEM imaging procedure to show specific molecular localization in large-scale EM sections of mouse and marmoset brain. Target molecules were labeled with antibodies and sequentially visualized in cryostat sections using fluorescence and gold particles. Fluorescence images were obtained by light microscopy immediately after antibody staining. Immunostained sections were postfixed for EM, and silver-enhanced sections were dehydrated in a graded ethanol series and embedded in resin. Ultrathin sections for EM were prepared from fully polymerized resin blocks, collected on silicon wafers, and observed by multibeam scanning electron microscopy (SEM). Multibeam SEM has made rapid, large-area observation at high resolution possible, paving the way for the analysis of detailed structures using the CLEM approach. Here, we describe detailed methods for large-area CLEM in various tissues of both rodents and primates.

全件表示 >>

このページの先頭へ▲

KOARA（リポジトリ）収録論文等 【 表示 ／ 非表示 】

全件表示 >>

このページの先頭へ▲

総説・解説等 【 表示 ／ 非表示 】

  • Spontaneous intramural duodenal hematoma as the manifestation of Noonan syndrome

    Yamazawa K., Yamada Y., Kuroda T., Mutai H., Matsunaga T., Komiyama O., Takahashi T.

    American Journal of Medical Genetics, Part A （American Journal of Medical Genetics, Part A）  176 （ 2 ） 496 - 498 2018年02月

    ISSN  15524825

  • Proliferation and differentiation characteristics of neural stem cells during course of cerebral cortical histogenesis

    Mitsuhashi T, Takahashi T.

    Congenital Anomalies 56   6 - 11 2016年

    記事・総説・解説・論説等（学術雑誌）, 共著,  ISSN  1741-4520

    　概要を見る

    Recent advancements in the research field of stem cell biology have enabled the realization of regenerative medicine in various systems of the body, including the central nervous system. However, fundamental knowledge regarding how neural stem cells divide and generate young neurons in mammals, especially in vivo, is still inadequate. In this article, we shall summarize the concept of cell cycle/division of neural stem cells that generate projection neurons in the murine cerebral cortex. We shall also review the molecular mechanisms that modulate the critical parameters related to the cell cycle regulatory mechanisms, with special reference to the cell cycle regulatory protein p27Kip1 , an inhibitor of progression of the cell cycle at the G1 phase. A better understanding of the mechanisms controlling cell cycle progression is expected to contribute to the development of novel strategies to increase the efficiency of neural cell/tissue production, both in vivo and in vitro.

  • 脳幹・小脳の発生異常 小児疾患診療のための病態生理

    高橋孝雄, 三橋隆行.

    小児内科 48   247 - 251 2016年

    記事・総説・解説・論説等（商業誌、新聞、ウェブメディア）, 共著

  • 〔長期予後と成人後の医学的問題〕小児神経疾患

    高橋孝雄, 三橋隆行

    日本医師会雑誌 143 （ 10 ） 2135 - 8 2015年

    記事・総説・解説・論説等（学術雑誌）, 共著

  • 大脳皮質の発生と難治性てんかん

    高橋孝雄, 三橋隆行

    脳と発達 46   187 - 190 2014年

    記事・総説・解説・論説等（学術雑誌）, 共著

全件表示 >>

このページの先頭へ▲

研究発表 【 表示 ／ 非表示 】

  • Neurobiology of Neural Stem/Progenitor Cells and Its Application to Child Neurology.

    Takao Takahashi

    The 14th Asian and Oceanian Congress of Child Neurology, 

    2017年05月
    , 

    口頭発表（基調）

  • Valproic acid exposure in utero causes neocortical dysgenesis: Altered proliferation/differentiation pattern of neural progenitor cells

    K. FUJIMURA, T. MITSUHASHI, S. SHIBATA, S. SHIMOZATO, T. TAKAHASHI

    Neuroscience 2015, 

    2015年10月
    , 

    ポスター発表

  • In Utero Exposure to Valproic Acid Causes Cerebral Cortical Dysgenesis in Mice

    Kimino Fujimura, Takayuki Mitsuhashi, Shinsuke Shibata, Sachiko Shimozato, Takao Takahashi

    The 13th Asian and Oceania Congress of Child Neurology, 

    2015年05月
    , 

    ポスター発表

  • バルプロ酸ナトリウム胎内曝露がマウス大脳皮質発生に与える影響

    藤村公乃、三橋隆行、芝田晋介、下郷幸子、高橋孝雄

    第49回慶應ニューロサイエンス研究会, 

    2015年02月
    , 

    ポスター発表

  • 小児急性リンパ性白血病治療関連けいれんの原因の変遷

    小西 順子, 武内 俊樹, 下郷 幸子, 三橋 隆行, 高橋 孝雄

    第55回日本小児神経学会学術集会, 

    2013年06月
    , 

    口頭発表（一般）

全件表示 >>

このページの先頭へ▲

競争的研究費の研究課題 【 表示 ／ 非表示 】

  • 発達期精神疾患の発症基盤に胎内環境が与える影響の解析

    2020年04月
    -
    2023年03月

    文部科学省・日本学術振興会, 科学研究費助成事業, 高橋 孝雄, 基盤研究(B), 補助金,  研究代表者

  • 胎児脳・未熟脳における星状グリアの産生メカニズムの解明と治療応用にむけた 機能解析

    2017年04月
    -
    2020年03月

    科学研究費補助金(文部科学省・日本学術振興会）, 高橋孝雄, 補助金,  研究代表者

  • 母体低栄養がエピジェネティックに大脳皮質構築に与える影響に関する研究

    2016年04月
    -
    2019年03月

    科学研究費補助金(文部科学省・日本学術振興会）, 三橋隆行, 補助金,  研究分担者

  • 先天奇形症候群の大脳皮質発生異常にエピジェネティクス機構が果たす役割に関する研 究

    2014年04月
    -
    2017年03月

    科学研究費補助金(文部科学省・日本学術振興会）, 高橋孝雄, 補助金,  研究代表者

  • ヒストンメチル化機構の異常が神経幹細胞の細胞分裂動態に与える影響に関する 研究

    2013年04月
    -
    2016年03月

    科学研究費補助金(文部科学省・日本学術振興会）, 三橋隆行, 補助金,  研究分担者

全件表示 >>

このページの先頭へ▲

Works 【 表示 ／ 非表示 】

  • 医学部国際交流委員会委員

    2003年10月
    -
    2005年09月
    , 

    その他

  • 総合学習小委員会委員長

    2003年10月
    -
    2005年09月
    , 

    その他

  • 入学試験検討委員会委員

    2003年10月
    -
    2005年09月
    , 

    その他

  • 臨床実習に関する小委員会委員

    2003年10月
    -
    2005年09月
    , 

    その他

  • 学務委員会委員

    2003年10月
    -
    2005年09月
    , 

    その他

全件表示 >>

このページの先頭へ▲

受賞 【 表示 ／ 非表示 】

  • The Charles A.King Trust Medical Foundation,Young Investigator Award

    1992年

  • 三四会賞

    1994年, マウス胎仔の新皮質発生における細胞分裂様式

  • 成長科学協会研究奨励賞

    高橋孝雄, 1996年01月, 成長科学協会, 大脳新皮質発生における成長因子の役割

  • 東京都医師会研究奨励賞

    高橋孝雄, 1997年03月, 東京都医師会, 大脳皮質における細胞分裂に関する研究

  • 私立大学情報教育協会賞

    2005年, 患者データベースを用いた臨床実習システム

このページの先頭へ▲
 

担当授業科目 【 表示 ／ 非表示 】

  • 小児科学講義

    2024年度

  • 小児科学講義

    2023年度

  • 小児科学演習

    2022年度

  • 小児科学実習

    2022年度

  • 小児科学講義

    2022年度

全件表示 >>

このページの先頭へ▲

担当経験のある授業科目 【 表示 ／ 非表示 】

  • 小児科学

    慶應義塾

    2015年04月
    -
    2016年03月

  • メディカル・プロフェッショナルリズムⅥ

    慶應義塾

    2015年04月
    -
    2016年03月

このページの先頭へ▲
 

所属学協会 【 表示 ／ 非表示 】

  • 日本小児科学会　会長

    　

  • 日本小児神経学会　理事長

    　

  • 日本小児保健協会　理事

    　

  • 日本てんかん学会　評議員

    　
このページの先頭へ▲